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Proliferative vitreoretinopathy (PVR) is a disease of the retina in the human eye. Retinal 
pigment epithelium cells (RPE) undergo an epithelial to mesenchymal transition in 
response to retinal trauma. This transition gives the cells mobility and allows them to 
potentially infiltrate the vitreous chamber and deposit on either side of the retina. Once cell 
deposition has occurred, along with several other transformed cells derived from cell types 
such as Müller glia, these migratory cells can form a membrane contiguous with the retinal 
extracellular matrix and, upon contraction, cause wrinkling of the retina. If left untreated 
PVR can lead to traction retinal detachment and blindness.  
There are limitations to the methods currently being used to treat this disease. The most 
common treatment option for PVR is surgery, which has a limited success rate. 
Pharmacological agents, such as the protein kinase inhibitor dasatinib, are also being 
investigated for their efficacy in treating this condition. Dasatinib has been shown to 
prevent PVR and associated cellular functions in porcine animal models in a dose-
dependent manner. One of the limitations of using dasatinib, however, is the need for 
recurring drug injections to keep a therapeutic level in the eye and prevent retinal 
contracture.  
Targeted ocular drug delivery, through the use of polymeric nanoparticles, offers a 
promising method to deliver dasatinib to the eye without the need for frequent daily 
injections. In this project,  spray drying, a technique that produces drug-encapsulated 




particles. Particle size was optimized to produce particles under 1 µm in diameter through 
the use of a Taguchi statistical design approach. Particles were manufactured on a Büchi 
B-90 nanospray spray dryer. PLGA particle optimization was completed before the 
production of PLGA dasatinib particles. After PLGA particle optimization, PLGA-
dasatinib particles were produced (n = 3) and their size analyzed using scanning electron 
microscopy. The release kinetics of dasatinib from the PLGA particles was analyzed using 
UV-Visible spectroscopy from this the drug release kinetics and mechanism was 
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PLGA:   poly-lactic-co-glycolic acid 
PBS:  phosphate buffered saline 
PVR:  proliferative vitreoretinopathy 
RPE:   retinal pigment epithelium 
EMT:  epithelial mesenchymal transition 
ECM:  extracellular matrix 
PDGF:  platelet derived growth factor 
PDGFR:  platelet derived growth factor receptor 
DCM:   dichloromethane 
(w/v %):  percent weight by volume 
µm:   micrometer 
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L/min:   liters per minute 
BSA:   bovine serum albumin 
PLGA-D:   PLGA dasatinib particles 
PPV:                pars plana vitrectomy  
SEM:   scanning electron microscopy 
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I. INTRODUCTION  
A. Anatomy of the Eye: 
 
To understand the disease process of proliferative vitreoretinopathy it is useful to first 
understand the basic anatomy of the human eye. The shape of the human eye is an oblate 
spheroid that has three primary layers: the fibrous coat, vascular coat, and nervous coat.1 
A basic schematic of the anatomy of the eye can be seen in Figure 1. The outermost layer 
of the eye is the cornea which acts as a transparent meniscus lens that aids in focusing light 
on the retina.2,3 The cornea is the anterior 1/6 of the fibrous coat which comes in contact 
with the environment. The remaining 5/6 of the fibrous coat of the eye is made up of the 
sclera, which is commonly referred to as the whites of the eye. The sclera of the eye helps 
maintain ocular shape and protect the eye from trauma.4 The meeting point between the 
cornea and the sclera is known as the limbus.  
 




The vascular coat of the eye serves to nourish the eye and is made up of the iris, 
ciliary body, and choroid. The iris acts as a control point for the amount of light reaching 
the retina through dilation and constriction of the pupil.2 The lens of the eye is posterior to 
the iris. The space between the iris and the lens of the eye is known as the posterior 
chamber. The ciliary body of the eye controls the lens as well as aqueous humor 
production.6 The choroid is the main vascular tissue of the eye and provides nourishment 
to the organ.  
The nervous coat of the eye is composed of the retina, which is the part of the eye 
that is responsible for vision.  The retina is the innermost layer of the eye and contains 
specialized cells called rods and cones that help the eye process light through the 
conversion of the electromagnetic waves into neural impulses processed by the brain, 
Figure 2.4 
 




The retina lines the posterior portion of the eye and is around 0.5 mm in thickness.7 
It communicates with the brain through the optic nerve which inserts into the retina 
producing the optic disc, the blind spot in human vision.  The human retina has three layers 
of nerve cells and two layers of neuronal synapses, Figure 3.  
 
FIGURE 3. Anatomy of the human retina with neuronal layers8 
The cells that line the most posterior portion of the retina are the retina pigmented 
epithelium cells (RPE), which are a main contributor in the disease of proliferative 
vitreoretinopathy (PVR). The next layer of cells in the retina which contain the rods and 
cones which project into the RPE.8 Following the layer of rod and cone projections into the 
RPE is the outer nuclear layer which contains the cell bodies of the rods and cones. After 
this layer is the inner nuclear layer, followed by the inner plexiform layer, the ganglionic 




Light must travel through the layers of the retina before it is able to activate the rod 
and cone cells of the eye.9 After activating the cells through the absorption of photons the 
light is converted into a biochemical message that is further modified into an electrical 
signal which is transduced to the nervous cells of the retina and then relayed to the brain. 
The retinal pigment epithelium (RPE) lining the posterior portion of the eye is integral in 
the development of PVR.  
           The RPE is a monolayer of cells that is part of the blood retinal barrier.9 It plays a 
wide variety of roles in maintaining the retinal environment for the rods and cones which 
it intimately interacts with. The basolateral membrane of the RPE faces Bruch’s membrane. 
Microvilli on the apical surface of the RPE complex with the outer portions of the photo 
receptors and work to maintain the retinal microenvironment necessary for vision.  
 One of the RPE’s functions which is necessary for sight in the human eye is the 
absorption of light which is focused on the retina by the lens.9 The RPE forms a dark 
pigmented wall which aids in the absorption of scattered light. Another function of the RPE 
is ion transport between the photoreceptors of the eyes and the choriocapillaries. The large 
amount of metabolic turn over in the retina and intraocular pressure from the vitreous body 
to the retina produces water which must be removed from the retinal space. Water from the 
inner retina is transported by the Müller cells and water from the subretinal space is 
removed by the RPE. The RPE transports water and ions from the subretinal space into the 
choriocapillaries. In addition to moving water and ions the RPE also removes metabolic 
waste products produced by the photoreceptors.  
               Along with transporting water and electrolytes from the subretinal space to the 




photoreceptors of the eye.9 The RPE maintains the excitability of the rods and cones by 
transporting all-trans-retinal and isomerizing it to all-cis-retinal before returning it to the 
photoreceptors. Photoreceptor excitability is also maintained through the phagocytosis of 
worn out photoreceptors by the RPE. The RPE also secrets growth factors and 
immunosuppressive factors into the eye. The RPE plays many vital functions in the eye 
and a disruption in any one of the functions can result in damage to the retina and loss of 
vision.  
B. Proliferative Vitreoretinopathy 
The Retina Society Terminology defined proliferative vitreoretinopathy as the 
growth of cellular membranes on the anterior and posterior surfaces of the detached retina 
and the posterior hyaloids.10,11 PVR is marked by the migration of cells onto the retinal 
surfaces in response to chemical signals associated with wound healing. The disease 
process can be divided into several stages: cell migration and proliferation, extracellular 
collagen production and membrane development, and contracture of membrane that causes 
folding and/or detachment of the retina.12 This contracture of the retina proceeds tractional  
retinal detachment and is the most common cause for retinal detachment following surgical 
interventions.13 In 1981 the Retina Society Terminology classified the physiological 
conditions previously known as massive vitreous retraction (MVR), massive preretinal 
retraction (MPR), massive periretinal proliferation (MPP) and massive preretinal 
fibroplasia (MPF) under the name of PVR and classified the disease into grades of 
severity.14  
Retinal detachment from the underlying retinal pigment epithelium (RPE) can be 




detachment causes tissue trauma and induces inflammatory and wound healing responses 
of the body that can lead to PVR.11,17,18 Several cell types have been implicated to play 
roles in PVR including: retinal pigment epithelium, mononuclear leukocytes, microglia, 
and Müller glia. In the first few days following retinal injury, proliferation of Müller cells 
occurs.16 In the normal retina, Müller glial cells cover the entire retina, providing it with 
structural and metabolic support. In response to injury, reactive Müller cell gliosis occurs 
and is thought to be a protective mechanism to prevent further tissue damage and promote 
retinal repair. This response by the Müller cells is associated with the release of 
proinflammitory cytokines and growth factors, which in the adult mammalian retina can 
lead to further degeneration and damage.  
The RPE is a single layer of cells that lines the Bruch’s membrane. RPE cells gain 
access to the vitreous cavity through retinal holes and/or tears that often accompany retinal 
detachment.19 Loss of cell-cell adhesion triggers cells to undergo an epithelial-
mesenchymal transition (EMT) rendering them similar to fibroblasts in morphology. This 
transition changes  epithelial cells phenotypes to display one associated with mesenchymal 
cells including increased mobility, resistance to apoptosis, increased ECM production, and 
greater invasive properties.20,21 These cells are further stimulated to proliferate by a 
combination of growth factors/cytokines from the vitreous and inflammation that includes 
transforming growth factor beta (TGF-β), platelet-derived growth factor (PDGF), and 
thrombin.22 
Both activated Müller cells and RPE cells that have undergone EMT can further be 




muscle actin (α-SMA).23 Myofibroblasts are considered to play a critical role in various 
fibrotic diseases including PVR. 
Various growth factor receptors such as platelet-derived growth factor receptors 
(PDGFR) have been found in the epiretinal membranes formed in PVR.24,25 Kazlauskas 
and colleagues have conducted a series of studies demonstrating the importance of 
PDGFR-α in PVR associated cellular functions in vitro and in a rabbit model of PVR in 
vivo. Such receptors can be targeted molecularly through the use of pharmaceutical agents, 
including the drug dasatinib.26 Targeting these cellular growth factors may be used to 
prevent or slow the formation of PVR in the eye.  
 
C. Current Treatments and Limitations 
Surgery is currently the preferred method of treatment for PVR.12 The aim of retinal 
surgery is to alleviate retinal traction and repair the break in the retina to reinstate as much 
healthy retinal anatomy as possible. The most common procedure performed for PVR is 
pars plana vitreoctomy with membrane peeling.15 Light to moderate cases of PVR are most 
easily treated with surgery, while severe PVR requires complicated surgery, as examined 
by Mendes, e. al.27 The study evaluated retinectomy to treat severe proliferative 
vitreoretinopathy. Thirty-eight patients with PVR grade C3, which is considered severe 
PVR, underwent retinectomy which increased the rates of final retinal reattachment. 
Various drugs and pharmacological agents including anti-inflammatory drugs, 




Anti-inflammatory drugs are commonly used to try to prevent PVR.12 Proteometric 
analysis of the vitreous samples of patients with PVR has shown up-regulation of 
inflammatory markers.  Triamcinolone (a glucocorticoid) was first used by Jones, et al. 
along with pars plana vitrectomy (PPV) and silicone oil with conflicting results. Prednisone 
is another anti-inflammatory commonly used to treat this physiological condition, but 
requires further research to determine its efficacy. Other pharmacological agents that have 
been used to treat the disease among which is  5-fluorouracil an antiproliferative agent.  
Antiproliferative agents have been used to treat PVR with mixed 
results.13Antiproliferative agents are used to inhibit the cell cycle and cellular proliferation 
of RPE cells following the break in the retina. The most commonly used antiproliferative 
agent is 5-fluorouracil (5-FU). It inhibits thymidine formation, thereby preventing DNA 
synthesis in actively proliferating cells. When used in clinical trials 5-FU was shown to 
reduce the rate of postoperative PVR following rhegmatogenous retinal detachment 
surgery (RRD).29 
Cellular growth pathway inhibitors, such as those that interfere with kinase 
enzymes, are another method being examined to control PVR.13,30 Kinases participate in 
transducing extracellular signaling into gene expression changes such as EMT. Inhibiting 
signaling pathways involved in PVR has been shown to prevent EMT, thus preventing 
formation of the epiretinal membrane.20 Ranibizumab, a vascular endothelial growth factor 
inhibitor, has been shown to prevent PVR in rabbit models.15 Kinase inhibitors work later 





D. Dasatinib and Proliferative Vitreoretinopathy: 
Dasatinib is a dual tyrosine kinase inhibitor developed to inhibit SRC family 
kinases and Abl kinase.31 Dasatinib is currently Food and Drug Administration (FDA) 
approved for the treatment of chronic myeloid leukemia under the trade name of 
Sprycel.32,33 Umazume, et al. tested dasatinib’s ability to prevent the PVR-associated 
cellular changes on cultured RPE cells from swine.34 A porcine in vivo model for PVR was 
subsequently used to evaluate the level of retinal traction in the eye caused by PVR. 
Dasatinib was shown to prevent RPE growth in a dose-dependent manner with a dose of 
0.1 µM inhibiting 80% of vitreous fluid-stimulated collagen gel contraction. A total of 
eleven porcine eyes were injected with dasatinib to look at the formation of the retinal 
membrane and retinal traction. Due to the low residence time of dasatinib in the vitreous 
humor, injections were made into the eyes on day 0, 3, 7, and 10. Only one of the eleven 
eyes injected with dasatinib presented with retinal detachment while all eleven control eyes 
had retinal detachment. The use of multiple injections of dasatinib to prevent the formation 
of PVR makes the drug an ideal candidate for a drug delivery system which would remove 
















FIGURE 4. Routes of ocular drug delivery35 
Drugs can be targeted to the eye through several different routes: intravitreal, 
subconjunctival, systemic application, and topical application among others.36 PVR is a 
disease that affects the retina, which is therefore the primary target area for drugs intended 
to prevent PVR pathology. The retina has several barriers that make drug delivery 
challenging.37 The blood retinal barrier (BRB) is the posterior barrier to drug delivery and 
the blood aqueous barrier (BAB) is the anterior barrier for drug delivery to the retina.38 The 
BRB restricts the permeability and diffusion of substances between the retina and the 
blood. It relies primarily on active transport to move substances across the barrier making 
passive drug diffusion difficult.30 The BAB is composed of the ciliary epithelium and the 
capillaries of the iris. Like the BRB its function is to tightly regulate substances that can 
get into the eye which makes drug delivery difficult.  
Topical drug delivery is appealing for drug delivery to the anterior portion of the 




diffusing through the layers of the eye to reach the retina.37 Less than 5% of the delivered 
topical dose has been shown to reach the deeper layers of ocular tissue.39 Additionally, 
enzymatic degradation of the drug occurs before it can reach the posterior segment of the 
eye.  
Systemic drug delivery typically has low ocular bioavailability of the drug, with 
between 1-2% reaching the posterior portion of the eye. The lack of drug reaching the 
posterior segment of the eye requires frequent injections to sustain necessary therapeutic 
levels. Systemic drug delivery also allows nonspecific absorption of the drug by other 
tissues.  
Drugs delivered into the eye cavity through periocular injection typically do not 
reach the retina because it lies behind the lens which acts as a barrier.36 The sclera of the 
eye provides a large surface area, though it has extensive blood vessel networks through 
which drugs can diffuse and be removed through before reaching the retina.  
Intravitreal injection is the most common method of drug injection to reach the 
posterior segment of the eye including the retina.39 Intravitreal injections have several 
shortcomings, however, such as the need for repeated injections.37 One of the ways 
researchers have tried to combat this problem is through increasing the drug residence time 
in the vitreous humor using a drug delivery vehicle.  
 
F. Controlled Drug Release 
Controlled drug release systems are an advancement in drug delivery technology 




increasing the ability of drugs to cross physiological barriers, prolonging drug release in 
situ and helping prevent premature release of the drug.36 The increased efficiency in 
delivering drugs to their target can be used to decrease the overall drug dosage and the 
amount of the drug needed for therapeutic levels.  
Nanoparticles/sub-micron particles, ranging in size from 10 – 1000 nm, have been 
researched extensively for use as drug delivery systems. For ophthalmologic drug delivery, 
particles are typically composed of either lipids, proteins, or polymers.39 Nanoparticles 
have been used for a long-term drug delivery solution to the posterior components of the 
eye. Once injected into the vitreous humor of the eye nanoparticles have been shown to 
accumulate on the RPE. The various drug release profiles of particles can be divided into 
slow sustained release and particles that experience a burst release followed by sustained 
release.40 The zero-order model of drug release kinetics is for nanoparticles which do not 
undergo disintegration and release the drug at a slow steady rate until no drug remains. The 
first order model of drug release kinetics can also be used to describe particles which did 
not experience an initial burst release and is typically seen in water soluble drugs in a 
porous matrix. The Higuchi model of drug release was first elucidated in 1961 and was 
used to describe drug release kinetics from planar systems. Takeru Higuchi developed the 
model based on drug release from thin ointment films which is modelled as drug release 
into a perfect sink.41 The Higuchi model of drug release is best used to predict drug release 
from a permeable matrix when the amount of drug released is greater than the solubility 
limit.42 The model, however, has since found utility in characterizing drug release in 
particles as well. The Hixon-Crowell model of drug release is used when the drug release 




exists in dissolvable tablets for drug delivery. The Korsmeyer-Peppas model of drug 
delivery was developed for drug release from a polymeric system. In addition to the above 
drug release kinetics, there are several “special application” models which have not been 
covered. 
 Particles employed for ocular drug release have shown a variety of drug 
release kinetics models. For example, chitosan sodium alginate nanoparticles used for 
ocular drug delivery were found to have an initial burst release followed by a longer 
sustained drug delivery period.43 Another set of chitosan nanoparticles loaded with 
cyclosporine A for the treatment of extraocular disease were also found to have an initial 
burst release followed by sustained drug release.44 Poly (lactic-co-glycolic) acid (PLGA) 
nanoparticles loaded with cyclosporine A showed a biphasic drug release profile and fit a 
Weibull model of drug release.45  
Three of the most common polymers for ocular drug delivery are: poly (alkyl 
cyanoacrylates), polycaprolactone, and poly (lactic-co-glycolic acid).46 PLGA is a 
biodegradable, nontoxic polymer that hydrolyzes into the nontoxic monomers lactic acid 
and glycolic acid. PLGA nanoparticles have been used to deliver drugs to the retina.47 One 
of the advantages of using PLGA as a drug delivery system is the tailorability of the drug 
to the needs of the research team.48 The release time of drugs encapsulated in a PLGA shell 
can be modified by varying the molecular weight of the polymer, the lactide:gylcolide ratio 
of the polymer, and altering how the polymer /drug is combined.  
Gupta, et. al. used PLGA to deliver sparfloxacin to improve precorneal penetration 
time and increase the amount of drug in the vitreous humor.46 Gavini, et. al. utilized PLGA 




research team found that the preparation of PLGA drug delivery vehicles was a suitable 
method of drug delivery. Gupta, et. al. used PLGA nanoparticles loaded with the drug 
sparfloxacin for ocular drug delivery for treatment of bacterial conjunctivitis.46 PLGA 
nanoparticles have been shown to increase the ocular bioavability of drugs in the eye but 
must be produced at a specific size range to prevent ocular irritation while still delivering 
enough of the drug to treat the desired condition. Particle size and polydispersity were 
found to influence the delivery of Sparfloxacin to the eye. PLGA nanoparticles under 250 
nm were considered optimal for ocular drug delivery. Ocular irritation was tested through 
the use of hen’s egg chorioallantoic membrane tests. Membrane tests were performed 
because they are sensitive, inexpensive and the chorioallontic membrane is a whole tissue 
that includes veins, arteries, and capillaries. Being a complete tissue, the chorioallontic 
membrane responds with a total inflammatory response and is an appropriate method of 
observing what biological reactions would occur in the eye. 
Another study by Chang, et al. looked at the biocompatibility of PLGA 
nanoparticles for ocular drug delivery.48 Albumin and doxycycline were fluorescently 
labeled and loaded into PLGA using a water-oil-water double emulsion method. 
Subconjunctival injections were used to evaluate the biocompatibility of PLGA particles 
with the eye in murine animal models. The mice in the study received conjunctival 
injections of 10 µL in both eyes and were euthanized after 14 days to observe the immune 
response to the particles. Particles were found to be biocompatible and no significant ocular 
inflammation was found. Drug release of the particles was also observed. The particles 
exhibited an initial burst release followed by a slow sustained release out to 20 days, 




particles loaded with pranoprofen for ocular drug delivery.50 The nanoparticles were 
synthesized using a solvent displacement technique with polyvinyl alcohol as a stabilizer. 
Ocular tolerance was tested using HET-CAM, and an irritation level of zero was obtained.  
As can be seen from the above studies, PLGA is a drug delivery system that allows 
customization based on the manufacturing parameters, the polymer itself and the drug 
utilized. The tailorability of PLGA as well as the low levels of ocular irritation found 
previously makes it an attractive drug delivery vehicle. There are several manufacturing 
methods in which PLGA nanoparticles can be manufactured. In this project, PLGA 
nanoparticles were synthesized using the spray drying manufacturing method which has 
four primary manufacturing parameters that can be controlled: PLGA concentration 
(w/v%), inlet temperature, flow rate, and lactide:gylcolide ratio of the PLGA.  
 
G. Spray Drying Manufacturing Method 
The spray drying manufacturing method of producing nanoparticles has a well-
documented history in scientific literature. It is a popular method to produce nanoparticles 
in both research and in industry.52 Spray drying generates solid powders through the fast 
drying of the carrier solvents.53,54 Understanding and controlling nanoparticle production 
has gained more interest in the last decade.55 With the increase of research in nanoparticles 
the spray drying manufacturing method has received more attention as a manufacturing 
method of nanoparticles for drug delivery. Particles produced via spray drying are known 




Use of the Büchi Nano B-90 has been shown to produce particles that are spherical 
with a high particle yield of up to 85% using a small amount of starting material.56 The 
Büchi B-90 has a vibrating mesh and an electrostatic particle collector which allow better 
control of the spray drying process.53,47 The mesh can reliably generate similarly sized 
nanoparticles and the electrostatic particle collector ensures a better yield. There are several 
parameters on the Büchi B-90 that can be controlled and changed when producing particles. 
Two of the parameters for this experiment were optimized using the Büchi B-90 including 
the air flow rate through the spray dryer and air inlet temperature, which indirectly controls 
the temperature of the spray head. The other variables in the experiment were based on the 
PLGA concentration and the amount of dasatinib used. Optimization of particle production 
using a Büchi B-90 has been previously attempted by Sree Harsha, et. al. To create particles 
of vitaglpitin, a new drug for diabetes, spray drying was optimized using three factors and 
observing their effect on the formulation of the particles.57 However, optimization of the 
spray drying process is sensitive to several factors, and thus must be repeated for each set 
of drug/polymer/solvent combinations. 
Lee et al. looked at the optimization of the spray drying of bovine serum albumin 
(BSA) for particle size and axial morphology on a Büchi B-90 using a Taguchi design 
approach.58 The levels that were used in this experiment were: spray mesh pore diameter, 
BSA solution concentration, surfactant concentration, drying air flow rate, and inlet 
temperature. The parameters that were found to have the most effect were spray mesh size 
and surfactant concentration. Lee, et. al. proved that nanoparticles sprayed on a Büchi B-
90 can successfully be optimized to hit the desired target parameters using a logical 












FIGURE 5. Büchi B-90 nano spray dryer59, 60  
A Büchi B-90 nano spray dryer (Büchi, New Castle, DE.)  was used to spray dry the 
PLGA and PLGA dasatinib (PLGA-D) particles (figure 5). There are several functional 
elements of the spray dryer that perform tasks necessary for particle formation.61At the 
top of the spray dryer there is a heating element and the spray head itself. The heating 
element heats the inlet air to the desired temperature and can produce temperatures up to 
120˚ C. Droplet formation is achieved through the use of an ultrasonic nebulizer.  
The ultrasonic nebulizer is in the spray head. It includes a piezoelectric actuator 
with a thin stainless-steel membrane that contains micron-sized pores. Different sized 




the desired particle size. This stainless-steel membrane vibrates at ultrasonic frequencies 
between 80-140 kHz which ejects droplets at the desired size. The droplets next encounter 
the drying chamber, which uses conductive heat exchange between the drying gas and the 
droplets.52 Particles form from the droplets as the solvent evaporate and are collected by 
an electrostatic particle collector located at the base of the spray drying unit. The Büchi B-
90 Nano spray dryer also contains an outlet filter that collects the finest particles for 
protection of the user and the environment. The drying gas is pumped into the drying 
chamber via either an aspirator or compressed air, with the air flow rate controlled via an 
inlet regulator. 
For the spray drying of PLGA and PLGA-D, a flammable organic solvent, 
dichloromethane, was utilized. This required the spray dryer to be operated with a Büchi 
B-295 Inert Loop system that allows the spray dryer to be operated with the exclusion of 
oxygen in the inlet gas. This prevents ignition of the solvent vapor, and also allows solvent 
recycling and reduces cost.  
As stated previously the Büchi B-90 can be optimized through careful experimental 
design to determine which parameters contribute the most to particle size.62 Spray drying 
on a Büchi B-90 presents a unique challenge because the machine has several different 
components which can be optimized. Additionally, the PLGA and dasatinib concentrations 
can also be studied to observe their effect on final particle size. Given the large number of 
variables, a rational design is needed such as the Taguchi design like the one used by Lee, 






I. Taguchi Matrix and Taguchi Design: 
Design of experiments can be used to optimize a procedure, however, once several 
variables become involved it becomes increasingly difficult and costly to perform. Taguchi 
matrix design allows for the optimization of manufacturing parameters through the control 
factors of the experiment. Taguchi design was developed by Dr. Genichi Taguchi and is a 
technique which reduces the number of experiments through an orthogonal array and 
minimization of out of control factors. Originally, it was used for improving the quality of 
manufactured goods but has found application in other fields such as engineering and 
biotechnology.64 
Taguchi design reduces the number of experiments that need to be performed and 
utilizes orthogonal arrays to achieve this. Orthogonal arrays are used to analyze many 
design factors simultaneously.53 A loss function is used to measure the performance 
characteristics that are deviating from the desired value.64 The value obtained from the loss 
function is transformed into a signal-to-noise (S/N) ratio. The S/N value measures the 
quality of the manufactured product with emphasis on product variation. Typically, the 
designated trials from the Taguchi matrix are performed, and the set of parameters that 









A. Chemical Supplies 
PLGA with three different lactide:gylcolide ratios (65:35, 50:50, 75:25) was 
purchased from Lactel Absorbal Polymers (Birmingham, AL).  Dichloromethane and 
phosphate buffered saline pH 7.4 (PBS) were supplied by Sigma-Aldrich (St. Louis, MO). 
Dasatinib was supplied by Toronto Research Chemicals (Ontario, Canada).  
B. Synthesis of PLGA and PLGA Dasatinib Solution: 
PLGA particles of various lactide:glycolide ratios were dissolved in 
dichloromethane at various weight by volume (% w/v) depending on the parameter 
requirements in the Taguchi matrix (Table 1). This mixture was then sonicated for 10 
minutes to ensure full dissolution of the PLGA into the DCM. The solution was kept on 
ice while being spray-dried.  
C. Spray Drying of PLGA Based on Taguchi Design: 
PLGA and PLGA dasatinib solutions were spray dried using a Büchi B-90 Nano 
spray dryer. Four parameters were manipulated to see what combination would yield the 
smallest PLGA particle size. The parameters that were manipulated were: PLGA 
concentration (w/v), lactide:glycolide linkage ratio of the PLGA, spray head inlet 
temperature, and the flow rate of the spray dryer. These parameters were chosen based on 
prior spray dries performed in the lab previously and by others. Schafroth, et al. also 




of inlet temperature, flow rate, lactide:glycolide ratio on PLGA particles.65 They found that 
the spray mesh diameter, sample flow rate, spray rate, and sample concentration had a 
profound effect on the size of the PLGA particles produced providing another example that 
spray drying parameters can be manipulated to optimize particle size.  
TABLE I. 
PARAMETERS FOR SPRAY DRYING PLGA PARTICLES 
PARAMETER DETAILS LEVEL  
1 2 3 
A PLGA concentration (w/v%) 1.5 2 2.5 
B Inlet temperature (°C) 40 45 50 
C Flow rate (L/min) 95 100 110 
D PLGA Ratio 
(lactide:glycolide) 
50:50 65:35 75:25 
  
The parameters that were used were as follows: PLGA (w/v %) = 1.5%, 2.0%, 
2.5%; Inlet temperature (ºC) = 40º, 45º, 50º; Flow rate (L/min) = 95, 100, 110; PLGA 
(lactide: glycolide ratio) = 50:50, 65:35, 75:25. Level values for each parameter were 
chosen based on Sree Harsha, et. al.  and prior experiments in the O’Toole lab.  A total of 
nine different spray-drying runs were performed based on the combinations produced in 
the Taguchi matrix. All nine PLGA sprays were done through a 4 µm spray mesh, as this 




Table 1 shows the levels and parameters that were used for PLGA spray drying runs based 
on the Taguchi matrix.  
TABLE II. 
TAGUHI MATRIX DESIGN RUNS AND LEVELS 








Run 1 1 1 1 1 
Run 2 1 2 2 2 
Run 3 1 3 3 3 
Run 4 2 1 2 3 
Run 5 2 2 3 1 
Run 6 2 3 1 2 
Run 7 3 1 3 2 
Run 8 3 2 1 3 
Run 9  3 3 2 1 
Dry particles were collected from the collecting drum using a nanoparticle scraper 
manufactured by Büchi.  
D. Spray Drying of PLGA Based on Best Taguchi Design 
Following optimization, PLGA particles were spray-dried using the parameters in 
the Taguchi matrix that yielded the smallest particle size, which was trial 1. Based on 
analysis of the original Taguchi results three more spray drying trials of just PLGA were 
completed using lower percent weight by volume (w/v %). The w/v % variations were: 
0.25%, 0.5%, and 1% with all other parameters held the same as in trial  
E. Spray Drying of PLGA Dasatinib Particles 
PLGA dasatinib (PLGA-D) particles were produced using the same method as the 
particles manufactured for the Taguchi optimization with the further synthesis step of the 




the PLGA particles from Trial 1 which yielded the smallest particles. 0.025% dasatinib 
w/v%, and 0.5% 50:50 PLGA were used in the synthesis of the new PLGA-D particles. 
Dasatinib was then added to the PLGA/DCM mixture. The solution was then sonicated for 
10 minutes to ensure full dissolution of the PLGA and dasatinib in the DCM.  
 PLGA dasatinib particles were spray dried using the following parameters:  
40°C, 95 L/min flow rate, 0.5 (w/v%) 50:50 PLGA, and 0.025 (w/v%) dasatinib. These 
parameters were chosen because they yielded the smallest PLGA particles. Different w/v 
% of dasatinib were loaded into the particles to see how dasatinib loading affected particle 
size and morphology. 
F. Particle Characterization: 
 










FIGURE 7. Plasma coater65 
All particles were characterized using a Zeiss Supra 35 field emission scanning 
electron microscope (Carl Zeiss Microscopy, LLC, Thornwood NY) shown in Figure 6. 
Samples were prepared on SEM sample tacks and sputter coated for 30s with 
gold/palladium using a plasma coater from International Scientific Instruments (New 
Dehli, India seen in Figure 7. Images from the SEM were taken using EHT = 2 kV. ImageJ 
software was utilized to analyze the particle diameter.67 For each Taguchi trial, a total of 
ten different images were used with 100 particles being measured per image for a total of 
n = 1000 particles. SEM images of the Taguchi trials can be seen in the appendix. Particle 
diameter was based on the longest axial measurement of the particle. Statistical comparison 
of particle size was performed using student t-tests with a p-value of 0.05.  
The second optimization set of PLGA particles utilizing differing w/v% PLGA 
were characterized using a minimum of 100 particles per image with at least five different 
SEM images used per condition.  PLGA-D particles were characterized with a minimum 
of 1000 particles per condition. 
In addition to the SEM images, particle stability in 1x PBS was analyzed using zeta 
potential measurements on a ZetaPALS (Brookhaven). Higher absolute Zeta potential 
values were interpreted to correlate with higher particle stability. 
 




PLGA particle size optimization was performed through the use of a Taguchi 
matrix. The parameters that were optimized can be seen in Table 1. Each parameter that 
was optimized had three different levels which were chosen based on prior spray drying 
done with PLGA in the O’Toole lab as well as other laboratories.  Particle optimization 
was based on minimizing particle diameter. Particle sizes were measured using ImageJ 
software calibrated to the 10 µm scale bar on the SEM images. Signal-to-noise ratio (S/N) 





where n is the number of observations (in this case the number of particles measured 
utilizing IMAGE J) and y is the output that is being measured (particle size). The S/N ratio 
is used in the Taguchi design to identify the set of parameters that produce the desired 
product with the least amount of noise.68 Noise is uncontrollable variability inherent to a 
manufacturing procedure. The S/N ratio shows which parameters on the Taguchi matrix 
produce particles with the lowest uncontrolled variation. This equation is used to minimize 
the occurrence of undesirable particle characteristics such as particles that are too large. 69 
 
H.Dasatinib Release Studies 
A zero-time point release value was collected by rinsing 7 mg of PLGA dasatinib particles 
in 1x phosphate buffer solution (PBS). The PBS was then removed using a pipet and 
measurement of dasatinib content in the rinsed solution was measured using the UV-VIS 




absorbance of 325 nanometers (nm). New 1x PBS was then added to the PLGA dasatinib 
pellets and the dispersions were placed in a Thermo Scientific Series 8000 DH CO2 
incubator at 37˚C and allowed to sit for 24 hours. After 24 hours had passed the 1x PBS 
was removed utilizing a pipet and dasatinib quantified using the absorbance value at 325 
nm. Measurement of PBS and subsequent replacement of fresh 1x PBS was performed for 
a total of 30 days. 
 
FIGURE 8. Dasatinib UV-Vis calibration curve 
A calibration curve was prepared using dasatinib dissolved into 1x PBS the concentrations 
of dasatinib used and the corresponding UV-VIS peaks obtained from the machine can be 
seen in Figure 8  
III. RESULTS AND DISCUSSION  


























PLGA and PLGA-D particles with sizes larger than one micrometer were produced in an 
earlier study in the O’Toole lab. The release profiles of the particles were studied as was 
their stability in 1x PBS, which presents a baseline for comparing the particles produced 
utilizing the Taguchi matrix for optimization. Larger particles showed greater instability in 
1x PBS as measured through zeta potential. Particles greater than 1 µm in size also showed 
varied release profiles with release of dasatinib up to 40 days with seemingly random 
release kinetic behavior. Larger particles also exhibited noticeable swelling and PLGA 
aggregation at 15 days of suspension in the PBS.  
B. PLGA and PLGA-D Optimization 
 
 
A total of nine trials were performed using the Taguchi matrix. All nine trials used a 4 µm 
mesh with dichloromethane as the solvent. 
T1 T2 T3 T4 T5 T6 T7 T8 T9



















Taguchi Matrix Particle Size Distribution




All trials were sprayed with the PLGA DCM solution kept on ice to keep the suspension 
cold to reduce solvent evaporation and material degradation. Figure 9 shows a histogram 
of the particle sizes that were obtained. Particle size and axial ratio was measured using 
ImageJ software. Trial 1 produced the smallest particles with a size of 1.21 ± 0.6 µm.  
 
 
The axial ratio of the particles is used to determine how circular the particles are by 
measuring diameters across the apparent largest and smallest diameters of each particle. A 
particle with an axial ratio measurement of 1 was considered spherical.70 5 images with 
100 particles per image (500 total) were used to measure the axial ratio. As can be seen 
from Table 3 all nine spray drying trials exhibited nearly spherical morphologies without 
significant fluctuation in particle shape. Additionally, all particles had a smooth or slightly 
rough surface appearance (see appendix). 





















1 1 1 1 1  1.20(0.61) -2.55  1.07 -1.74 
2 1 2 2 2  1.87(0.60) -5.87  1.03 -1.61 
3 1 3 3 3  1.64(0.65) -4.94  1.03 -1.08 
4 2 1 2 3  1.88(0.71) -6.06  1.09 -2.06 
5 2 2 3 1  2.46(0.80) -8.25  1.02 -1.24 
6 2 3 1 2  1.60(0.55) -4.51  1.00 0.01 
7 3 1 3 2  1.68(0.69) -5.16  1.07 -1.81 
8 3 2 1 3  1.53(0.97) -4.95  1.10 -1.52 
9 3 3 2 1  1.54(0.91) -5.02  1.02 -0.44 
           
TABLE III 





The impact of each of the four parameters used to spray dry the particles was then evaluated 
by averaging the S/N ratio for all trials that shared a specific parameter level (e.g. A1). 
After averaging each parameter level, the range for the given parameter was determined by 
finding the difference between the highest and lowest S/N ratios within the parameter. 
The effect on particle size can be seen 
in Table 4 and the effect on axial ratio 
can be seen in Table 5.  Particle size 
was prioritized as the main target 
outcome over particle circularity due 
to heightened immune response in 
swine eyes with larger particles found in 
previous PLGA studies in the lab.  
The parameters which had the largest effect on the particle size were the air flow rate of 
the spray dryer and the w/v % of PLGA used to make the particles. However, regulation 
of the absolute air flow rate while operating the Büchi 
B-90 in closed loop mode is erratic. The system relies 
on input gas supplies from two different air cylinders 
(N2 and CO2) and the input is only triggered after a 
minimum air pressure threshold is reached within the 
spray dryer. As a result, system pressure and resulting 
air flow could vary up to 50% during a single spray 
drying run. Considering this, it was determined to focus on changing the PLGA 
concentration, as this is a much more reliable and easily controlled parameter. The 
LEVEL A B C D 
1 -4.46 -4.59 -4 -5.27 
2 -6.27 -6.35 -5.65 -5.18 
3 -5.04 -5.04 -6.12 -5.32 
RANGE 1.81 1.76 2.12 0.05 
RANK 2 3 1 4 
LEVEL A B C D 
1 -1.48 -1.87 -1.08 -1.14 
2 -1.10 -1.46 -1.37 -1.14 
3 -1.26 -0.50 -1.38 -1.55 
RANGE 0.38 1.37 0.30 0.41 
RANK 3 1 4 2 
TABLE IV. 
Parameter level effect on particle size 
TABLE V. 




parameters with the greatest impact on the axial ratio of the particles were the inlet 
temperature and lactide:glycolide ratio in the PLGA. The axial ratio measurements of the 
particles in Table 6 show that all of the particles exhibited an axial ratio measurements 
close to 1. 
Use of the Taguchi approach allowed us to identify a set of parameters within our 
matrix to produce the smallest particles, but more importantly, allowed us to identify which 
parameters had the most effect on the outcome (particle size). Due to ease of adjusting 
PLGA concentration, and the fact that intense immune responses were observed for larger 
PLGA particles when injected into our porcine models (data not shown), we decided to 
experiment with changing the particle size to levels outside of our original set of levels. As 
Trial 1 produced the smallest particles out of all of the trials, the parameters that were used 
for Trial 1 were 1.5% PLGA (w/v %), 40˚C inlet temperature, 95 L/min flow rate, and 
50:50 PLGA lactide:gylcolide linkage ratio were chosen as starting points for further 
experiments. 
TABLE VI. 
Varying PLGA w/v% effect on particle size and axial ratio 
The same S/N ratio used in our Taguchi approach was used to evaluate the impact of 
varying w/v % PLGA on the particle size while adding trials with 0.5 and 1.0 w/v% PLGA. 
SEM analysis of these extra trials showed that the lower the w/v% of the PLGA the smaller 








y(n=3) SNR (dB) y(n=3) SNR (dB) 
1.5 1.20(0.61) -2.55 1.07 -1.74 
1.0 0.83(0.37) 0.51 1.00 0.14 




produced to see the effect of lowering the particle size. 0.25% w/v% PLGA particles did 
not have a spherical morphology and as such were not desirable to go forward with for this 
study images of these particles can be seen in the appendix.  Particles produced with 0.5% 
PLGA w/v were the smallest size at 0.73 ± 0.4 µm while still maintaining a circular axial 
ratio of 1.02. These particles were considered most suitable for future in vivo studies, and 
so these spray drying parameters were used for trials in which dasatinib was included for 

















y(n=3) SNR (dB) y(n=3) SNR (dB) 
1 0.76(0.32) 1.64 1.00 -0.15 
2 0.73(0.35) 1.89 1.00 -0.48   
3 0.64(0.28) 3.10 1.01 -0.99 
Figure 10. SEM of PLGA-D T1 Figure 12. SEM of PLGA-D T2 
Figure 11. SEM of PLGA-D T3 
TABLE VII. 




PLGA dasatinib (PLGA-D) particles were produced using the parameters for trial 1 with a 
different w/v% PLGA of 0.5 because it had produced the smallest particles while 
maintaining a spherical shape. The particles were spray dried with 0.025 w/v% dasatinib. 
The concentration of dasatinib was chosen to maintain the minimum therapeutic level  
 found in prior studies such as the one by Umazume, et. al. over the desired release period. 
Additionally, previous studies in the laboratory with PLGA-D showed that increasing from 
0.025% (w/v) of dasatinib up to 0.25% (w/v) only increased the encapsulation efficiency 
by 1.9-2.2 times. Supporting information from the previous PLGA-D encapsulation studies 
can be seen in the appendix. From these experiments it was determined that using higher 
concentrations of dasatinib for spray drying was not cost effective. Three sets of PLGA-D 
particles were produced. Representative SEM images of each one of the three sets of 
particles can be seen in Figures 10, 11, and 12.  
 
 As can be seen from the SEM images all three sets of particles exhibited a 
nearly spherical morphology which is corroborated by the axial ratio measurements in 
Table 7 which are all close to 1. Two sets of the particles exhibited a perfectly spherical 
morphology with an axial ratio score of 1.0. The last set of particles produced had an axial 
ratio value of 1.01. The sizes of the particles that were produced were 0.76 ± 0.32 µm, 0.73 
± 0.35 µm, and 0. 64 ± 0.28 µm. All three sets of particles hit a size below the  
SUB-MICROMETER PARTICLES(µM) ZETA POTENTIAL (MV) STDEV(MV) 
0.76 ± 0.32  -17.32 4.81 
0.73 ± 0.35  -20.69 3.27 
0.64 ± 0.28 -29.93 2.11 
Table VIII. 




target of 1 µm and exhibited the desired spherical morphology. Hela cells were found to 
internalize more spherically shaped gold nanoparticles over rod shaped nanoparticles.19 
Wooley, et. al. found that smaller spherical micelles had greater cellular uptake than larger 
spherical micelles indicating that smaller more spherical nanoparticles increase cellular 
uptake. Particle diameters were determined using ImageJ analysis of 8000 particles from 
ten different SEM images.  
The three sets of submicrometer particles exhibited enhanced stability as measured by the 
zeta potential Table VIII when compared to previous micrometer sized particles.  Table A2 
in the appendix shows the zeta potential of PLGA and PLGA-D particles produced both in 
this study and previously in the O’Toole lab. Submicrometer particles had a more negative 
zeta potential which is considered to be less toxic to cells due to the cationic charge cells 
have.71 Shao, et. al. found that 
polymeric nanoparticles with a 
more negative zeta potential 
displayed less cytotoxicity 
than polymeric nanoparticles 
with a positive zeta potential.72 
Nanoparticles (NP) with a 
negative zeta potential were 
found to cause less damage to 
cells due to their reduced 
interaction with the cell membrane, and to undergo phagocytosis easier than their positively 
charged counterparts. Negatively charged NPs were found to have weak interactions with 




lysosomes and the protein coronas that form around them due to the coronas also being 
negatively charged.  
Positively charged NPs were shown by Shao, et. al. to disrupt the formation of lysosomal 
membranes and alter biological processes. A controlled release study was performed on all 
three sets of PLGA-D particles and the results are shown in Figure 13.  
The particles released detectable amounts of dasatinib out to 14 days. Unlike the larger 
particles produced earlier in the study, the submicrometer particles all showed the same 
drug release profile. The submicrometer particles had a rapid initial release of the drug with 
60% of the dasatinib in the particles being released by the second day of the study. The 
submicrometer particles released 94% of their dasatinib concentration within the first week 
of the experiment and followed the Korsmeyer-Peppas  model of drug release mechanisms 
with Fickian Diffusion.  The particle release matching to the Korsmeyer-Peppas model can 
be seen in the appendix.   
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As can be seen from the graphs of the particle release kinetics all three sets of 
submicrometer particles fit the same release profile whereas the larger particles produced 
previously had different release profiles. Two additional sets of PLGA-D particles were 
produced with the same parameters.  
The two additional sets of particles that were produced were both under a micrometer in 
size with sizes of: 0.97 ± 0.43 µm and 0.89 ± 0.57 µm, although their drug release   kinetics 
were not determined. The large standard deviations are due to fluctuations in internal 
pressure of the spray dryer in the inert loop system which is a hallmark characteristic of 
the spray drying manufacturing method.  
IV. CONCLUSIONS AND RECOMMENDATIONS 
Through use of a Taguchi statistical design, it has been shown that PLGA and PLGA 
dasatinib particles smaller than one micrometer can be produced. These particles displayed 
a spherical morphology with axial ratio measurements close to one. PLGA-D particle size 
and morphology effects the immunological reaction by the body and the cellular uptake of 
the particles. The smaller particle size and spherical morphology increases cellular uptake 
and reduce immune response.  
When loaded with dasatinib, all the submicrometer particles exhibited uniform release 
kinetics and conformed to the Korsmeyer-Peppas release profile. The particles showed 
rapid release of dasatinib with sustained dasatinib release up to 14 days. When compared 
to larger PLGA and PLGA dasatinib particles produced previously in the lab, the smaller 
particles exhibited greater stability as measured through zeta potential. More negative zeta 




 Further study could involve cellular contraction assays to observe the particles 
effectiveness at preventing the contracture of retinal pigment epithelium. Additional work 
that could be done is injecting optimized particles into animal models to observe how they 
behave in vivo. A recommended animal study would be injecting the PLGA-D particles 



















Taguchi matrix PLGA SEM images  
 
Figure A1.  SEM image of Taguchi Trial 1 
  
 





Figure A3. SEM image of Taguchi Trial 3 
 





Figure A5. SEM image of Taguchi Trial 5 
 














Figure A8.  SEM image of Taguchi Trial 8 
 






















Submicrometer Particle Release Kinetics 
 












Figure A11.  Trial 2 PLGA-D Particle Release Mechanisms  




































































Figure A12.  Trial 3  PLGA-D Particle Release Mechanisms  
Zeta Potential of PLGA and PLGA-D particles 
PLGA-DASATINIB (µM) ZETA POTENTIAL (MV) 
0.76  ± 0.32 -17.32 ± 4.81 
0.73  ± 0.35 -20.69 ± 3.27 
0.64 ± 0.28 -29.93 ± 2.11 
1.27 ± 0.58 -3.95 ± 6.00 
1.11 ± 0.63 5.99 ± 12.74 
1.01 ± 0.33 -1.72 ± 2.60 
Table A1.  Zeta potential measurements of PLGA dasatinib particles 
 
 PLGA (µM) ZETA POTENTIAL (MV) 
0.83  ± 0.37 -10.02 ± 1.38 
0.73  ± 0.40 -38.39 ± 3.55 
0.62 ± 0.20 -48.2 ± 1.43 
1.20 ± 0.61 24.42 ± 13.4 
1.63 ± 1.56 -16.95 ± 17.03 
1.11 ± 0.28 -2.3 ± 11.09 
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